Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

IGNITION Anti-IgLON5 disease: From Neuroinflammation to Neurodegeneration

Coordinator
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Spain
Runs
1 November 2025 to 31 October 2029
Status
Running
EU funding
€3.7m
Total cost
—
Partners
23 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227384

What the project is doing

In the project's own words, from its summary on CORDIS.

Anti-IgLON5 disease is a recently described encephalopathy associated with a variety of neurological symptoms that can be life-threating. The clinical course is mainly chronic and the response to immunotherapies is suboptimal. The hallmark of the disease is the presence of antibodies against IgLON5, a cell adhesion molecule predominantly expressed on the neuronal membrane. Surprisingly, neuropathological findings on autopsies revealed the presence of an atypical neuronal brainstem tauopathy, establishing a link between neurodegeneration and IgLON5 antibodies.

IGNITION aims to establish an innovative, interdisciplinary doctoral training program to foster the next generation of scientists at the interface of neuroinflammation and neurodegeneration. The unique program will train 13 Doctoral Candidates across four key objectives: 1) addressing clinical challenges in diagnosing and managing anti-IgLON5 disease, 2) investigating the role of neuroinflammation in neurodegeneration, 3) developing animal models for therapeutic testing, and 4) analysing the function of IgLON5 in health and disease.

These objectives will be pursued using cutting-edge molecular, cellular, and in vivo techniques, offering a comprehensive research training experience with the support of leading biotech and diagnostic companies. IGNITION will advance our understanding of the mechanisms behind anti-IgLON5 disease, contributing to scientific innovation and providing tools for improved diagnosis and prognosis. The gained insights will extend to the broader field of neurodegeneration, offering potential breakthroughs for other tauopathies, including Alzheimer’s and Parkinson’s disease.

Through its research and training activities, IGNITION will foster scientific excellence, increase disease awareness, and provide societal and economic benefits through the development of new diagnostic and therapeutic strategies across Europe.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Argen-XZwijnaardeBelgiumAssociatedpartner
Christian-Albrechts-Universitaet Zu KielKielGermanyAssociatedpartner
Euroimmun Medizinische Labordiagnostika AGLubeckGermanyAssociatedpartner
Gesellschaft zur Förderung der Lebenswissenschaften Heidelberg GmbHHeidelbergGermanyAssociatedpartner
Sonja NossWiesbadenGermanyAssociatedpartner
Universitatsklinikum JenaJenaGermanyParticipant
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Biosystems SABarcelonaSpainParticipant
Carl Zeiss IberiaTres CantosSpainAssociatedpartner
Fundacio Institut De Ciencies FotoniquesCastelldefelsSpainAssociatedpartner
Hospital Clinic De BarcelonaBarcelonaSpainAssociatedpartner
Panlab SluCornella de LlobregatSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite De BordeauxBordeauxFranceAssociatedpartner
Fondazione Human TechnopoleMilanoItalyParticipant
Universita HumanitasPieve EmanueleItalyAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Politechnika WroclawskaWroclawPolandParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Encephalitis Support GroupMaltonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI